vs
Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and BRT Apartments Corp. (BRT). Click either name above to swap in a different company.
BRT Apartments Corp. is the larger business by last-quarter revenue ($24.3M vs $13.5M, roughly 1.8× Assertio Holdings, Inc.). On growth, BRT Apartments Corp. posted the faster year-over-year revenue change (1.3% vs -57.9%). Over the past eight quarters, BRT Apartments Corp.'s revenue compounded faster (1.9% CAGR vs -35.4%).
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...
BRT Apartments Corp is a publicly traded real estate investment trust that owns, operates, and develops multi-family residential properties primarily across high-growth markets in the United States. Its core portfolio consists of garden-style and mid-rise apartment communities, serving diverse renter groups while targeting long-term asset value appreciation and stable dividend returns for its shareholders.
ASRT vs BRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.5M | $24.3M |
| Net Profit | — | $-4.3M |
| Gross Margin | — | — |
| Operating Margin | -86.7% | -14.3% |
| Net Margin | — | -17.8% |
| Revenue YoY | -57.9% | 1.3% |
| Net Profit YoY | — | -108.7% |
| EPS (diluted) | $-4.54 | $-0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.5M | $24.3M | ||
| Q3 25 | $49.5M | $24.4M | ||
| Q2 25 | $29.2M | $24.2M | ||
| Q1 25 | $26.5M | $24.1M | ||
| Q4 24 | $32.2M | $24.0M | ||
| Q3 24 | $29.2M | $24.4M | ||
| Q2 24 | $31.1M | $23.9M | ||
| Q1 24 | $32.4M | $23.4M |
| Q4 25 | — | $-4.3M | ||
| Q3 25 | $11.4M | $-2.7M | ||
| Q2 25 | $-16.4M | $-2.6M | ||
| Q1 25 | $-13.5M | $-2.4M | ||
| Q4 24 | — | $-2.1M | ||
| Q3 24 | $-2.9M | $-2.2M | ||
| Q2 24 | $-3.7M | $-2.3M | ||
| Q1 24 | $-4.5M | $-3.2M |
| Q4 25 | -86.7% | -14.3% | ||
| Q3 25 | 23.2% | -13.7% | ||
| Q2 25 | -27.5% | -12.2% | ||
| Q1 25 | -50.0% | -11.3% | ||
| Q4 24 | -41.9% | -14.3% | ||
| Q3 24 | -10.4% | -11.7% | ||
| Q2 24 | -11.6% | -11.6% | ||
| Q1 24 | -13.4% | -14.0% |
| Q4 25 | — | -17.8% | ||
| Q3 25 | 23.1% | -11.1% | ||
| Q2 25 | -56.0% | -10.6% | ||
| Q1 25 | -51.1% | -9.8% | ||
| Q4 24 | — | -8.6% | ||
| Q3 24 | -10.0% | -9.0% | ||
| Q2 24 | -11.8% | -9.8% | ||
| Q1 24 | -13.9% | -13.5% |
| Q4 25 | $-4.54 | $-0.23 | ||
| Q3 25 | $0.11 | $-0.14 | ||
| Q2 25 | $-0.17 | $-0.14 | ||
| Q1 25 | $-0.14 | $-0.12 | ||
| Q4 24 | $-3.28 | $-0.10 | ||
| Q3 24 | $-0.03 | $-0.12 | ||
| Q2 24 | $-0.04 | $-0.13 | ||
| Q1 24 | $-0.05 | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.4M | $25.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $94.0M | $177.2M |
| Total Assets | $267.0M | $709.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.4M | $25.1M | ||
| Q3 25 | $93.4M | $21.1M | ||
| Q2 25 | $98.2M | $23.6M | ||
| Q1 25 | $87.3M | $24.4M | ||
| Q4 24 | $100.1M | $27.9M | ||
| Q3 24 | $88.6M | $45.8M | ||
| Q2 24 | $88.4M | $18.9M | ||
| Q1 24 | $80.7M | $21.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $38.6M | — |
| Q4 25 | $94.0M | $177.2M | ||
| Q3 25 | $105.8M | $186.7M | ||
| Q2 25 | $93.3M | $192.1M | ||
| Q1 25 | $108.5M | $198.5M | ||
| Q4 24 | $121.1M | $205.0M | ||
| Q3 24 | $130.5M | $209.9M | ||
| Q2 24 | $132.2M | $214.7M | ||
| Q1 24 | $134.5M | $220.7M |
| Q4 25 | $267.0M | $709.8M | ||
| Q3 25 | $319.8M | $714.2M | ||
| Q2 25 | $273.8M | $699.6M | ||
| Q1 25 | $286.4M | $703.9M | ||
| Q4 24 | $284.7M | $713.5M | ||
| Q3 24 | $276.0M | $717.7M | ||
| Q2 24 | $279.4M | $694.7M | ||
| Q1 24 | $282.0M | $699.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-30.0M | $14.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-30.0M | $14.1M | ||
| Q3 25 | $-4.8M | $9.1M | ||
| Q2 25 | $19.1M | $8.5M | ||
| Q1 25 | $-12.5M | $246.0K | ||
| Q4 24 | $11.5M | $24.1M | ||
| Q3 24 | $-35.0K | $9.0M | ||
| Q2 24 | $7.4M | $6.9M | ||
| Q1 24 | $7.5M | $653.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASRT
| Products | $12.8M | 95% |
| Other | $719.0K | 5% |
BRT
| Unconsolidated Joint Ventures | $13.2M | 54% |
| Other | $11.1M | 46% |
